-
Something wrong with this record ?
The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis
M. Wozniakova, J. Skarda, M. Raska
Language English Country Switzerland
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2021
PubMed Central
from 2021
Medline Complete (EBSCOhost)
from 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1995
- MeSH
- Immunity MeSH
- Immunotherapy MeSH
- Colorectal Neoplasms * pathology MeSH
- Humans MeSH
- Tumor Microenvironment * MeSH
- Prognosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Colorectal cancer (CRC) is one of the most common cancers worldwide. The patient's prognosis largely depends on the tumor stage at diagnosis. The pathological TNM Classification of Malignant Tumors (pTNM) staging of surgically resected cancers represents the main prognostic factor and guidance for decision-making in CRC patients. However, this approach alone is insufficient as a prognostic predictor because clinical outcomes in patients at the same histological tumor stage can still differ. Recently, significant progress in the treatment of CRC has been made due to improvements in both chemotherapy and surgical management. Immunotherapy-based approaches are one of the most rapidly developing areas of tumor therapy. This review summarizes the current knowledge about the tumor microenvironment (TME), immune response and its interactions with CRC development, immunotherapy and prognosis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025173
- 003
- CZ-PrNML
- 005
- 20221031100527.0
- 007
- ta
- 008
- 221017s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/pore.2022.1610502 $2 doi
- 035 __
- $a (PubMed)35936516
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Wozniakova, Maria $u Institute of Pathology and Molecular Genetics, University Hospital Ostrava, Ostrava, Czechia $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czechia
- 245 14
- $a The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis / $c M. Wozniakova, J. Skarda, M. Raska
- 520 9_
- $a Colorectal cancer (CRC) is one of the most common cancers worldwide. The patient's prognosis largely depends on the tumor stage at diagnosis. The pathological TNM Classification of Malignant Tumors (pTNM) staging of surgically resected cancers represents the main prognostic factor and guidance for decision-making in CRC patients. However, this approach alone is insufficient as a prognostic predictor because clinical outcomes in patients at the same histological tumor stage can still differ. Recently, significant progress in the treatment of CRC has been made due to improvements in both chemotherapy and surgical management. Immunotherapy-based approaches are one of the most rapidly developing areas of tumor therapy. This review summarizes the current knowledge about the tumor microenvironment (TME), immune response and its interactions with CRC development, immunotherapy and prognosis.
- 650 12
- $a kolorektální nádory $x patologie $7 D015179
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunita $7 D007109
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a nádorové mikroprostředí $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Skarda, Jozef $u Institute of Pathology and Molecular Genetics, University Hospital Ostrava, Ostrava, Czechia $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czechia
- 700 1_
- $a Raska, Milan $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czechia
- 773 0_
- $w MED00180530 $t Pathology oncology research $x 1532-2807 $g Roč. 28, č. - (2022), s. 1610502
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35936516 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100525 $b ABA008
- 999 __
- $a ok $b bmc $g 1854732 $s 1176463
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 28 $c - $d 1610502 $e 20220721 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
- LZP __
- $a Pubmed-20221017
